Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.76 |
| ▸ | MEN1 | O00255 | 2/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.76 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | CASP7 | P55210 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | NSD2 | O96028 | 1/20 | 0.55 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.53 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.53 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | GRM5 | P41594 | 1/20 | 0.50 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7248947 | 0.86 | MAPT (1.00) | MAPTMEN1KMT2AALDH1A1GAA | |
| SCHEMBL29580531 | 0.86 | MAPT (0.87) | MAPTMEN1KMT2AALDH1A1GAA | |
| SCHEMBL30606801 | 0.86 | MAPT (0.87) | MAPTMEN1KMT2AALDH1A1GAA | |
| SCHEMBL24987217 | 0.82 | MAPT (0.80) | MAPTMEN1KMT2AALDH1A1GAA | |
| SCHEMBL4117070 | 0.82 | MAPT (0.80) | MAPTMEN1KMT2AALDH1A1GAA | |
| SCHEMBL6585108 | 0.82 | MAPT (0.80) | MAPTMEN1KMT2AALDH1A1GAA | |
| SCHEMBL4111003 | 0.79 | MAPT (0.74) | MAPTMEN1KMT2AALDH1A1GAA | |
| SCHEMBL4104514 | 0.79 | MAPT (0.74) | MAPTMEN1KMT2AALDH1A1GAA | |
| SCHEMBL4121354 | 0.79 | MAPT (0.74) | MAPTMEN1KMT2AALDH1A1GAA | |
| SCHEMBL11193042 | 0.79 | MEN1 (0.74) | MAPTMEN1KMT2AALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240173287-A1 | Application Of PI4KIIIA Protein And Related Membrane Protein Complex In Treating Alzheimer's Disease | JIANGSU NUO-BETA PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2024-05-30 | — | — | US | disclosed |
| US-11766420-B2 | Application of PI4KIIIA protein and related membrane protein complex in treating alzheimer's disease | Jiangsu Nuo-Beta Pharmaceutical Technology Co. Ltd. (CN) | 2023-09-26 | — | — | US | disclosed |
| EP-3290525-B1 | METHOD FOR SCREENING DRUG AND THERAPEUTIC TARGET USED FOR TREATING ALZHEIMER'S DISEASE | JIANGSU NUO BETA PHARMACEUTICAL TECH CO LTD (CN) | 2022-02-23 | — | — | EP | disclosed |
| US-11236378-B2 | Method for screening drug and therapeutic targets used for treating Alzheimer's disease | Jiangsu Nuo-Beta Pharmaceutical Technology Co. Ltd. (CN) | 2022-02-01 | — | — | US | disclosed |
| US-20190314321-A1 | Application Of PI4KIIIA Protein And Related Membrane Protein Complex In Treating Alzheimer's Disease | JIANGSU NUO-BETA PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2019-10-17 | — | — | US | disclosed |
| US-20190211371-A1 | Method For Screening Drug And Therapeutic Targets Used For Treating Alzheimer's Disease | JIANGSU NUO-BETA PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2019-07-11 | — | — | US | disclosed |
| EP-3290514-A1 | APPLICATION OF PI4KIII PROTEIN AND RELATED MEMBRANE PROTEIN COMPLEX IN TREATING ALZHEIMER'S DISEASE | Jiangsu Nuo-Beta Pharmaceutical Technology Co., Ltd. (CN) | 2018-03-07 | — | — | EP | disclosed |
| EP-3290525-A1 | METHOD FOR SCREENING DRUG AND THERAPEUTIC TARGET USED FOR TREATING ALZHEIMER'S DISEASE | Jiangsu Nuo-Beta Pharmaceutical Technology Co., Ltd. (CN) | 2018-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190314321-A1 | Application Of PI4KIIIA Protein And Related Membrane Protein Complex In Treating Alzheimer's Disease | PI4K2A, PI4K2B, PIP4K2A | MAPT 406/4885MEN1 4528/4885KMT2A 3723/4885 |
| US-11236378-B2 | Method for screening drug and therapeutic targets used for treating Alzheimer's disease | PSD, TBRG4, ACTR3 | MAPT 222/4885MEN1 4346/4885KMT2A 4099/4885 |
| US-11766420-B2 | Application of PI4KIIIA protein and related membrane protein complex in treating alzheimer's disease | PI4K2A, PI4K2B, PIP4K2A | MAPT 406/4885MEN1 4528/4885KMT2A 3723/4885 |
| US-20240173287-A1 | Application Of PI4KIIIA Protein And Related Membrane Protein Complex In Treating Alzheimer's Disease | PI4K2A, PI4K2B, PIP4K2A | MAPT 406/4885MEN1 4528/4885KMT2A 3723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.